

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

Phosphorylated Met

RRID:AB_2143884

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3077, RRID:AB_2143884

Antibody Information

URL: http://antibodyregistry.org/AB_2143884

Proper Citation: Cell Signaling Technology Cat# 3077, RRID:AB_2143884

Clonality: unknown

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10328091, AB_10329175, AB_2143884, AB_2235289, AB_2315156.

Antibody Name: Phosphorylated Met

Description: This unknown targets

Defining Citation: [PMID:20853516](#)

Antibody ID: AB_2143884

Vendor: Cell Signaling Technology

Catalog Number: 3077

Record Creation Time: 20250819T231334+0000

Record Last Update: 20250820T044058+0000

Ratings and Alerts

No rating or validation information has been found for Phosphorylated Met.

No alerts have been found for Phosphorylated Met.

Data and Source Information

Usage and Citation Metrics

We found 55 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yoshichika R, et al. (2026) Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer. *Cancer immunology, immunotherapy* : CII, 75(4).

Wang Y, et al. (2026) A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. *Cellular oncology (Dordrecht, Netherlands)*, 49(1), 31.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Bowman CL, et al. (2025) The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. *Cancer research*, 85(24), 4899.

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. *Molecular cancer therapeutics*, 24(8), 1265.

Kang J, et al. (2025) Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response. *Journal of experimental & clinical cancer research* : CR, 44(1), 290.

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Schimmel MF, et al. (2025) Development of a cyst-targeted therapy for polycystic kidney disease using an antagonistic dimeric IgA monoclonal antibody against cMET. *Cell reports. Medicine*, 6(9), 102335.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Cui Y, et al. (2025) MET receptor tyrosine kinase promotes the generation of functional synapses in adult cortical circuits. *Neural regeneration research*, 20(5), 1431.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Poliakov?? Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. *Cancer research communications*, 4(7), 1863.

Seenan V, et al. (2024) Ovulation provides excessive coagulation and hepatocyte growth factor signals to cause postoperative intraabdominal adhesions. *iScience*, 27(6), 109788.

Deng Y, et al. (2024) LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. *Nature metabolism*, 6(9), 1756.

Rojas-Chaverra NM, et al. (2024) A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model. *iScience*, 27(8), 110426.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. *Cancer research communications*, 4(2), 337.

Zhou CQ, et al. (2024) Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts. *Cancer research communications*, 4(9), 2308.

Ye F, et al. (2024) Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion. *Cell reports*, 43(4), 114002.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.